CAMP and Graves disease: Conversely, the hCAP-18 plasma levels from patients with ataxia telangiectasia, glucose-6-phosphate dehydrogenase deficiency, Graves’ disease or Hyper IgE syndrome, were within the higher range as compared to patients with SCN (Table 4).